Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

Leigh Turner

doi:10.1016/j.stem.2020.05.003

Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

Leigh Turner

Center for Bioethics

Research output: Contribution to journal › Comment/debate › peer-review

31 Scopus citations

Abstract

In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.

Original language	English (US)
Pages (from-to)	806-810
Number of pages	5
Journal	Cell Stem Cell
Volume	26
Issue number	6
DOIs	https://doi.org/10.1016/j.stem.2020.05.003
State	Published - Jun 4 2020

Bibliographical note

Funding Information:
L.T. has reported to the FDA numerous businesses selling unlicensed and unproven stem cell interventions. On a pro bono basis, L.T. filed an expert opinion report and rebuttal report supporting plaintiffs in a lawsuit filed against a business marketing purported stem cell interventions. L.T. was also deposed in this case and was examined and cross-examined in a court hearing. This work was also conducted on a pro bono basis. L.T. is a member of the International Society for Cell and Gene Therapy and a member of the International Society for Stem Cell Research.

Publisher Copyright:
© 2020 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.stem.2020.05.003

Find It

Find It at U of M Libraries

Cite this

@article{3e12f52ea8b04bdbae4d6b6e7afb5d62,

title = "Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19",

abstract = "In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.",

author = "Leigh Turner",

note = "Funding Information: L.T. has reported to the FDA numerous businesses selling unlicensed and unproven stem cell interventions. On a pro bono basis, L.T. filed an expert opinion report and rebuttal report supporting plaintiffs in a lawsuit filed against a business marketing purported stem cell interventions. L.T. was also deposed in this case and was examined and cross-examined in a court hearing. This work was also conducted on a pro bono basis. L.T. is a member of the International Society for Cell and Gene Therapy and a member of the International Society for Stem Cell Research. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jun,

day = "4",

doi = "10.1016/j.stem.2020.05.003",

language = "English (US)",

volume = "26",

pages = "806--810",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Preying on Public Fears and Anxieties in a Pandemic

T2 - Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

AU - Turner, Leigh

N1 - Funding Information: L.T. has reported to the FDA numerous businesses selling unlicensed and unproven stem cell interventions. On a pro bono basis, L.T. filed an expert opinion report and rebuttal report supporting plaintiffs in a lawsuit filed against a business marketing purported stem cell interventions. L.T. was also deposed in this case and was examined and cross-examined in a court hearing. This work was also conducted on a pro bono basis. L.T. is a member of the International Society for Cell and Gene Therapy and a member of the International Society for Stem Cell Research. Publisher Copyright: © 2020 Elsevier Inc.

PY - 2020/6/4

Y1 - 2020/6/4

N2 - In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.

AB - In the midst of a global public health emergency, some businesses are taking advantage of widespread fears by marketing purported stem cell treatments for COVID-19. Such businesses target prospective clients with misleading claims, expose patients to potentially risky stem cell-based products, and undermine efforts to develop evidence-based treatments for COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85085491393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085491393&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2020.05.003

DO - 10.1016/j.stem.2020.05.003

M3 - Comment/debate

C2 - 32464095

AN - SCOPUS:85085491393

SN - 1934-5909

VL - 26

SP - 806

EP - 810

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 6

ER -

Preying on Public Fears and Anxieties in a Pandemic: Businesses Selling Unproven and Unlicensed “Stem Cell Treatments” for COVID-19

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this